Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study

S. C. Schulz, D. P. van Kammen, M. S. Buchsbaum, R. H. Roth, P. Alexander, W. E. Bunney

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Gamma-hydroxybutyrate (GHB) was administered to seven chronic schizophrenic patients in the first double-blind, placebo-replacement trial of this compound. No significant drug effect in this group was obtained. Two patients became nonpsychotic during the drug trial, three got worse and two patients did not respond. The two patients who responded with improvement were augmenters, as measured by average evoked potential (EP), had low platelet MAO activity and high cerebrospinal fluid (CSF) homovanillic acid (HVA). A number of patients developed akathisia and dystonia during the trial, especially after receiving probenecid for lumbar puncture. Further study is warranted, possibly in a selected patient group.

Original languageEnglish (US)
Pages (from-to)129-138
Number of pages10
JournalPharmacopsychiatria
Volume14
Issue number4
StatePublished - Dec 1 1981

Fingerprint

Sodium Oxybate
Schizophrenia
Therapeutics
Probenecid
Psychomotor Agitation
Homovanillic Acid
Spinal Puncture
Dystonia
Monoamine Oxidase
Evoked Potentials
Pharmaceutical Preparations
Cerebrospinal Fluid
Blood Platelets
Placebos

Cite this

Schulz, S. C., van Kammen, D. P., Buchsbaum, M. S., Roth, R. H., Alexander, P., & Bunney, W. E. (1981). Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study. Pharmacopsychiatria, 14(4), 129-138.

Gamma-hydroxybutyrate treatment of schizophrenia : A pilot study. / Schulz, S. C.; van Kammen, D. P.; Buchsbaum, M. S.; Roth, R. H.; Alexander, P.; Bunney, W. E.

In: Pharmacopsychiatria, Vol. 14, No. 4, 01.12.1981, p. 129-138.

Research output: Contribution to journalArticle

Schulz, SC, van Kammen, DP, Buchsbaum, MS, Roth, RH, Alexander, P & Bunney, WE 1981, 'Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study', Pharmacopsychiatria, vol. 14, no. 4, pp. 129-138.
Schulz SC, van Kammen DP, Buchsbaum MS, Roth RH, Alexander P, Bunney WE. Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study. Pharmacopsychiatria. 1981 Dec 1;14(4):129-138.
Schulz, S. C. ; van Kammen, D. P. ; Buchsbaum, M. S. ; Roth, R. H. ; Alexander, P. ; Bunney, W. E. / Gamma-hydroxybutyrate treatment of schizophrenia : A pilot study. In: Pharmacopsychiatria. 1981 ; Vol. 14, No. 4. pp. 129-138.
@article{9b1a5291446f4eab90d512c466f52db1,
title = "Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study",
abstract = "Gamma-hydroxybutyrate (GHB) was administered to seven chronic schizophrenic patients in the first double-blind, placebo-replacement trial of this compound. No significant drug effect in this group was obtained. Two patients became nonpsychotic during the drug trial, three got worse and two patients did not respond. The two patients who responded with improvement were augmenters, as measured by average evoked potential (EP), had low platelet MAO activity and high cerebrospinal fluid (CSF) homovanillic acid (HVA). A number of patients developed akathisia and dystonia during the trial, especially after receiving probenecid for lumbar puncture. Further study is warranted, possibly in a selected patient group.",
author = "Schulz, {S. C.} and {van Kammen}, {D. P.} and Buchsbaum, {M. S.} and Roth, {R. H.} and P. Alexander and Bunney, {W. E.}",
year = "1981",
month = "12",
day = "1",
language = "English (US)",
volume = "14",
pages = "129--138",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - Gamma-hydroxybutyrate treatment of schizophrenia

T2 - A pilot study

AU - Schulz, S. C.

AU - van Kammen, D. P.

AU - Buchsbaum, M. S.

AU - Roth, R. H.

AU - Alexander, P.

AU - Bunney, W. E.

PY - 1981/12/1

Y1 - 1981/12/1

N2 - Gamma-hydroxybutyrate (GHB) was administered to seven chronic schizophrenic patients in the first double-blind, placebo-replacement trial of this compound. No significant drug effect in this group was obtained. Two patients became nonpsychotic during the drug trial, three got worse and two patients did not respond. The two patients who responded with improvement were augmenters, as measured by average evoked potential (EP), had low platelet MAO activity and high cerebrospinal fluid (CSF) homovanillic acid (HVA). A number of patients developed akathisia and dystonia during the trial, especially after receiving probenecid for lumbar puncture. Further study is warranted, possibly in a selected patient group.

AB - Gamma-hydroxybutyrate (GHB) was administered to seven chronic schizophrenic patients in the first double-blind, placebo-replacement trial of this compound. No significant drug effect in this group was obtained. Two patients became nonpsychotic during the drug trial, three got worse and two patients did not respond. The two patients who responded with improvement were augmenters, as measured by average evoked potential (EP), had low platelet MAO activity and high cerebrospinal fluid (CSF) homovanillic acid (HVA). A number of patients developed akathisia and dystonia during the trial, especially after receiving probenecid for lumbar puncture. Further study is warranted, possibly in a selected patient group.

UR - http://www.scopus.com/inward/record.url?scp=0019721069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019721069&partnerID=8YFLogxK

M3 - Article

C2 - 7280012

AN - SCOPUS:0019721069

VL - 14

SP - 129

EP - 138

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 4

ER -